Literature DB >> 11719465

Increased p53 mutation frequency during tumor progression--results from a breast cancer cohort.

T Norberg1, S Klaar, G Kärf, H Nordgren, L Holmberg, J Bergh.   

Abstract

The mutational patterns of the p53 gene for exons 4-9 were analyzed in 30 recurring tumors compared with the p53 status of the corresponding 30 primary breast cancers. The prevalence of p53 mutations was higher, although not statistically significant (P = 0.07), in the evaluable recurring tumors compared with the corresponding primaries, 12 of 29 (41%) versus 7 of 30 (23%). Twenty-one of the patients had unchanged p53 mutation status in the recurring compared with the primary tumors, whereas 8 had an altered mutational status or pattern in the sequential tumor. These findings indicate that p53 mutations may be an important factor for tumor progression in human breast cancer.

Entities:  

Mesh:

Year:  2001        PMID: 11719465

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells.

Authors:  Yong-Yu Liu; Gauri A Patwardhan; Kaustubh Bhinge; Vineet Gupta; Xin Gu; S Michal Jazwinski
Journal:  Cancer Res       Date:  2011-01-28       Impact factor: 12.701

2.  TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.

Authors:  Hervé Bonnefoi; Martine Piccart; Jan Bogaerts; Louis Mauriac; Pierre Fumoleau; Etienne Brain; Thierry Petit; Philippe Rouanet; Jacek Jassem; Emmanuel Blot; Khalil Zaman; Tanja Cufer; Alain Lortholary; Elisabet Lidbrink; Sylvie André; Saskia Litière; Lissandra Dal Lago; Véronique Becette; David A Cameron; Jonas Bergh; Richard Iggo
Journal:  Lancet Oncol       Date:  2011-05-11       Impact factor: 41.316

3.  p53siRNA therapy reduces cell proliferation, migration and induces apoptosis in triple negative breast cancer cells.

Authors:  Cornelia Braicu; Valentina Pileczki; Alexandru Irimie; Ioana Berindan-Neagoe
Journal:  Mol Cell Biochem       Date:  2013-06-04       Impact factor: 3.396

4.  Sample-specific perturbation of gene interactions identifies breast cancer subtypes.

Authors:  Yuanyuan Chen; Yu Gu; Zixi Hu; Xiao Sun
Journal:  Brief Bioinform       Date:  2021-07-20       Impact factor: 11.622

5.  Breast cancer risk in relation to TP53 codon 72 and CDH1 gene polymorphisms in the Bangladeshi women.

Authors:  Samia Shabnaz; Maizbha Uddin Ahmed; Md Siddiqul Islam; Md Reazul Islam; Mir Md Abdullah Al-Mamun; Mohammad Safiqul Islam; Abul Hasnat
Journal:  Tumour Biol       Date:  2015-12-14

6.  Upregulation of KIF11 in TP53 Mutant Glioma Promotes Tumor Stemness and Drug Resistance.

Authors:  Bin Liu; Gang Zhang; Shukun Cui; Guoliang Du
Journal:  Cell Mol Neurobiol       Date:  2021-01-25       Impact factor: 5.046

7.  Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway.

Authors:  H Joshi; G Bhanot; A-L Børresen-Dale; V Kristensen
Journal:  Br J Cancer       Date:  2012-10-18       Impact factor: 7.640

8.  The Pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of BAX and p21, and increased breast cancer risk.

Authors:  Katharina Proestling; Alexandra Hebar; Nina Pruckner; Erika Marton; Ursula Vinatzer; Martin Schreiber
Journal:  PLoS One       Date:  2012-10-10       Impact factor: 3.240

9.  CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.

Authors:  Ranjan Chrisanthar; Stian Knappskog; Erik Løkkevik; Gun Anker; Bjørn Østenstad; Steinar Lundgren; Elisabet O Berge; Terje Risberg; Ingvil Mjaaland; Lovise Maehle; Lars Fredrik Engebretsen; Johan Richard Lillehaug; Per Eystein Lønning
Journal:  PLoS One       Date:  2008-08-26       Impact factor: 3.240

10.  Successful pregnancy after breast cancer therapy: dream or reality?

Authors:  Konstantinos Kontzoglou; Michael Stamatakos; Sofia Tsaknaki; Helen Goga; Alkiviades Kostakis; Michael Safioleas
Journal:  Int Semin Surg Oncol       Date:  2009-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.